Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu.

Aegis regularly reviews and updates its NPS testing menu to maintain clinical relevance and align with recommendations from the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologists (SOFT) NPS Committee. The latest update incorporates CFSRE’s tier one and tier two scope recommendations for Q2 2025.

CFSRE recently added two new categories to its scope recommendations: “Semi-synthetic Cannabinoids” and “Miscellaneous.” Semi-synthetic cannabinoids will now be included in Aegis’s traditional cannabinoid test, while synthetic cannabinoids will remain a separate orderable test code. Additionally, the NPS testing menu now includes Spirochlorphine (a designer opioid, also known as R6890) and Ethylbromazolam, a designer benzodiazepine found in counterfeit Alprazolam tablets.

“These updates equip clinicians with critical insights into emerging substances in today’s drug supply, enabling more accurate detection and informed treatment decisions. By identifying psychoactive compounds that may interfere with recovery, we help providers support individuals in achieving their care goals,” said Dr. Josh Schrecker, Sr. Director of Clinical Affairs at Aegis Sciences Corporation.

“Our research-driven updates demonstrate Aegis’s commitment to anticipating drug trends and expanding testing capabilities. By adding new categories and compounds, we ensure our menu reflects the evolving landscape and provides clinicians with advanced tools for comprehensive patient care,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.

Health care practitioners can learn more about the updated test offering at: www.aegislabs.com.

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251216784769/en/

"These updates equip clinicians with critical insights into emerging substances in today’s drug supply, enabling more accurate detection and informed treatment decisions. "